Cell line name |
LN229/EGFR |
Accession |
CVCL_D2SN |
Resource Identification Initiative |
To cite this cell line use: LN229/EGFR (RRID:CVCL_D2SN) |
Comments |
Population: Caucasian. Transfected with: HGNC; 3236; EGFR (with a N-terminal GVAMPGAEDDVV = PA-tag and a C-terminal with a C-terminal DMVNPGLEDRIE = RAP-tag and GDGMVPPGIEDK = MAP-tag). Derived from site: In situ; Brain, right frontal parieto-occipital cortex. |
Sequence variations |
- Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line).
|
Disease |
Glioblastoma (NCIt: C3058) Glioblastoma (ORDO: Orphanet_360) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0393 (LN-229) |
Sex of cell |
Female |
Age at sampling |
60Y |
Category |
Cancer cell line |
Publications | PubMed=29090976; DOI=10.1089/mab.2017.0042 Itai S., Yamada S., Kaneko M.K., Chang Y.-W., Harada H., Kato Y. Establishment of EMab-134, a sensitive and specific anti-epidermal growth factor receptor monoclonal antibody for detecting squamous cell carcinoma cells of the oral cavity. Monoclon. Antib. Immunodiagn. Immunother. 36:272-281(2017) PubMed=32218834; DOI=10.3892/ol.2020.11384 Takei J., Kaneko M.K., Ohishi T., Kawada M., Harada H., Kato Y. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Oncol. Lett. 19:2809-2816(2020) |
Entry history |
Entry creation | 30-Jan-2024 |
Last entry update | 30-Jan-2024 |
Version number | 1 |
---|